There is growing concern among stakeholders that developers of cancer clinical trials tend to default to patient-reported outcome measures (PROMs) used in previous similar trials when deciding on which PROMs...
The Verdict
ClassificationUnsure
ConfidenceHigh confidence
Analyzedtext
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/9e8dd2ce-1726-4bcf-b6b8-e3879e226bcb)